NK cells interfere with the generation of resistance against mycoplasma respiratory infection following nasal-pulmonary immunization

Journal of Immunology

Volumn 183, Issue 4, 2009, Pages 2622-2631

  Bodhankar, Sheetal ^a   Woolard, Mathew D ^b   Sun, Xiangle ^a   Simecka, Jerry W ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; MYCOPLASMA PULMONIS ANTIGEN; UNCLASSIFIED DRUG; GANGLIOSIDE GM1; GANGLIOTETRAOSYLCERAMIDE;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ISOLATION; CELL POPULATION; CONTROLLED STUDY; FEMALE; IMMUNOCOMPETENT CELL; INFECTION RESISTANCE; LUNG INFECTION; LYMPH NODE; LYMPHOID CELL; MOUSE; MYCOPLASMOSIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SCID MOUSE; T CELL DEPLETION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL CULTURE; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; INNATE IMMUNITY; LYMPHOCYTE DEPLETION; METABOLISM; MICROBIOLOGY; MOUSE MUTANT; MYCOPLASMA PULMONIS; TRANSGENIC MOUSE; VACCINATION;

ADMINISTRATION, INHALATION; ANIMALS; ANTIGENS, BACTERIAL; CELLS, CULTURED; FEMALE; G(M1) GANGLIOSIDE; IMMUNITY, INNATE; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; MICE, SCID; MICE, TRANSGENIC; MYCOPLASMA INFECTIONS; MYCOPLASMA PULMONIS; RESPIRATORY TRACT INFECTIONS; VACCINATION;

EID: 70149104644     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0802180     Document Type: Article

References (51)

1. Simecka, J. W., J. K. Davis, M. K. Davidson, S. E. Ross, C. Stadtlander, and G. H. Cassell. 1992. Mycoplasma diseases of animals. In Mycoplasmas: Molecular Biology and Pathogenesis. J. Maniloff, R. N. McElhaney, L. R. Finch, and J. B. Baseman, eds. American Society for Microbiology, Washington, DC, pp. 391-415.
2. Foy, H. M., G. E. Kenny, M. K. Cooney, and I. D. Allan. 1979. Long-term epidemiology of infections with Mycoplasma pneumoniae. J. Infect. Dis. 139: 681-687.
3. Freymuth, F., A. Vabret, J. Brouard, F. Toutain, R. Verdon, J. Petitjean, S. Gouarin, J. F. Duhamel, and B. Guillois. 1999. Detection of viral Chlamydia pneumoniae and Mycoplasma pneumoniae infections in exacerbations of asthma in children. J. Clin. Virol. 13: 131-139.
4. Martin, R. J., H. W. Chu, J. M. Honour, and R. J. Harbeck. 2001. Airway inflammation and bronchial hyperresponsiveness after Mycoplasma pneumoniae infection in a murine model. Am. J. Respir. Cell Mol. Biol. 24: 577-582. (Pubitemid 32442765)
5. Cassell, G. H., J. R. Lindsey, R. G. Overcash, and H. J. Baker. 1973. Murine mycoplasma respiratory disease. Ann. NY Acad. Sci. 225: 395-412.
6. Lindsey, J. R., H. J. Baker, R. G. Overcash, G. H. Cassell, and C. E. Hunt. 1971. Murine chronic respiratory disease: significance as a research complication and experimental production with Mycoplasma pulmonis. Am. J. Pathol. 64: 675-708.
7. Lindsey, J. R., and H. Cassell. 1973. Experimental Mycoplasma pulmonis infection in pathogen-free mice: models for studying mycoplasmosis of the respiratory tract. Am. J. Pathol. 72: 63-90.
8. Foy, H. M. 1993. Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin. Infect. Dis. 17(Suppl. 1):S37-S46.
9. Dajani, A. S., W. A. Clyde, Jr., and F. W. Denny. 1965. Experimental infection with Mycoplasma pneumoniae (Eaton's agent). J. Exp. Med. 121: 1071.
10. Cassell, G. H., and B. C. Cole. 1981. Mycoplasmas as agents of human disease. N. Engl. J. Med. 304: 80-89.
11. Simecka, J. W. 2005. Immune responses following mycoplasma infection. In Mycoplasmas: Molecular Biology, Pathogenicity, and Strategies for Control. A. Blanchard and G. Browning, eds. Horizon Bioscience, Norfolk, U.K., pp. 485-534.
12. Taylor, G., D. Taylor-Robinson, and G. W. Fernald. 1974. Reduction of Mycoplasma pneumoniae-induced pneumonia in hamsters by immunosuppressive treatment with antithymocyte sera. J. Med. Microbiol. 7: 343.
13. Cartner, S. C., J. R. Lindsey, J. Gibbs-Erwin, G. H. Cassell, and J. W. Simecka. 1998. Roles of innate and adaptive immunity in respiratory mycoplasmosis. Infect. Immun. 66: 3485-3491. (Pubitemid 28347799)
14. Keystone, E. C., D. Taylor-Robinson, M. F. Osborn, L. Ling, C. Pope, and V. Fornasier. 1980. Effect of T-cell deficiency on the chronicity of arthritis induced in mice by Mycoplasma pulmonis. Infect. Immun. 27: 192-196.
15. Hickman-Davis, J. M., S. M. Michalek, J. Gibbs-Erwin, and J. R. Lindsey. 1997. Depletion of alveolar macrophages exacerbates respiratory mycoplasmosis in mycoplasma-resistant C57BL mice but not mycoplasma-susceptible C3H mice. Infect. Immun. 65: 2278-2282.
16. + Th cell associated inflammatory lesions during murine mycoplasma respiratory disease. J. Immunol. 168: 3493-3501.
17. Cassell, G. H., and J. K. Davis. 1978. Protective effect of vaccination against Mycoplasma pulmonis respiratory disease in rats. Infect. Immun. 21: 69-75.
18. Hodge, L. M., and J. W. Simecka. 2002. Role of upper and lower respiratory tract immunity in resistance to mycoplasma respiratory disease. J. Infect. Dis. 186: 290-294.
19. Woolard, M. D., D. Hudig, L. Tabor, J. A. Ivey, and J. W. Simecka. 2005. NK cells in γ-interferon-deficient mice suppress lung innate immunity against Mycoplasma spp. Infect. Immun. 73: 6742-6751.
20. Walzer, T., M. Dalod, E. Vivier, and L. Zitvogel. 2005. Natural killer cell-dendritic cell crosstalk in the initiation of immune responses. Expert Opin. Biol. Ther. 5(Suppl. 1): S49-S59.
21. Woolard, M. D., L. M. Hodge, H. P. Jones, T. R. Schoeb, and J. W. Simecka. 2004. The upper and lower respiratory tracts differ in their requirement of IFN-γ and IL-4 in controlling respiratory mycoplasma infection and disease. J. Immunol. 172: 6875-6883.
22. Biron, C. A., K. B. Nguyen, G. C. Pien, L. P. Cousens, and T. P. Salazar-Mather. 1999. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17: 189-220.
23. Moretta, A. 2002. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat. Rev. Immunol. 2: 957-964.
24. Korsgren, M., C. G. Persson, F. Sundler, T. Bjerke, T. Hansson, B. J. Chambers, S. Hong, L. Van Kaer, H. G. Ljunggren, and O. Korsgren. 1999. Natural killer cells determine development of allergen-induced eosinophilic airway inflammation in mice. J. Exp. Med. 189: 553-562.
25. Davidson, M. K., J. K. Davis, J. R. Lindsey, and G. H. Cassell. 1988. Clearance of different strains of Mycoplasma pulmonis from the respiratory tract of C3H/HeN mice. Infect. Immun. 56: 2163-2168.
26. Simecka, J. W., and G. H. Cassell. 1987. Serum antibody and cellular responses in LEW and F344 rats after immunization with Mycoplasma pulmonis antigens. Infect. Immun. 55: 731-735.
27. Jones, H., L. Hodge, K. Fujihashi, H. Kiyono, J. R. McGhee, and J. W. Simecka. 2001. The pulmonary environment promotes Th2 cell responses after nasal-pulmonary immunization with antigen alone, but Th1 responses are induced during instances of intense immune stimulation. J. Immunol. 167: 4518-4526. (Pubitemid 32954330)
28. Kruisbeek, A. 1999. Isolation and fractionation of mononuclear cell populations. In Current Protocols in Immunology. J. E. Coligan, A. Kruisbeek, D. Margulies, E. Shevach, and W. Strober, eds. Wiley, New Yotk, pp. 3.1.1-3.1.5.
29. -/- mice. Nat. Med. 7: 557-562.
30. + T cell hyporesponsiveness at sites peripheral to filarial infection. J. Immunol. 176: 6918-6927.
31. Daley, J. M., A. A. Thomay, M. D. Connolly, J. S. Reichner, and J. E. Albina. 2008. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J. Leukocyte Biol. 83: 64-70.
32. Simecka, J. W., R. J. Jackson, H. Kiyono, and J. R. McGhee. 2000. Mucosally induced immunoglobulin E-associated inflammation in the respiratory tract. Infect. Immun. 68: 672-679.
33. Hodge, L. M., M. Marinaro, H. P. Jones, J. R. McGhee, H. Kiyono, and J. W. Simecka. 2001. Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization. Infect. Immun. 69: 2328-2338.
34. Cerwenka, A., and L. L. Lanier. 2001. Natural killer cells, viruses and cancer. Nat. Rev. Immunol. 1: 41-49. (Pubitemid 33741974)
35. Beilke, J. N., N. R. Kuhl, L. Van Kaer, and R. G. Gill. 2005. NK cells promote islet allograft tolerance via a perforin-dependent mechanism. Nat. Med. 11: 1059-1065.
36. Kelly, J. M., P. K. Darcy, J. L. Markby, D. I. Godfrey, K. Takeda, H. Yagita, and M. J. Smyth. 2002. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3: 83-90.
37. Medzhitov, R., and C. A. Janeway, Jr. 1998. Innate immune recognition and control of adaptive immune responses. Semin. Immunol. 10: 351-353. (Pubitemid 28499548)
38. Kos, F. J. 1998. Regulation of adaptive immunity by natural killer cells. Immunol. Res. 17: 303-312. (Pubitemid 28302188)
39. Zingoni, A., T. Sornasse, B. G. Cocks, Y. Tanaka, A. Santoni, and L. L. Lanier. 2005. NK cell regulation of T cell-mediated responses. Mol. Immunol. 42: 451-454.
40. Hayakawa, Y., V. Screpanti, H. Yagita, A. Grandien, H. G. Ljunggren, M. J. Smyth, and B. J. Chambers. 2004. NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J. Immunol. 172: 123-129. (Pubitemid 38020463)
41. Raziuddin, A., D. L. Longo, M. Bennett, R. Winkler-Pickett, J. R. Ortaldo, and W. J. Murphy. 2002. Increased bone marrow allograft rejection by depletion of NK cells expressing inhibitory Ly49 NK receptors for donor class I antigens. Blood 100: 3026-3033.
42. Satoskar, A. R., L. M. Stamm, X. Zhang, M. Okano, J. R. David, C. Terhorst, and B. Wang. 1999. NK cell-deficient mice develop a Th1-like response but fail to mount an efficient antigen-specific IgG2a antibody response. J. Immunol. 163: 5298-5302.
43. Yu, Y. Y., V. Kumar, and M. Bennett. 1992. Murine natural killer cells and marrow graft rejection. Annu. Rev. Immunol. 10: 189-213.
44. Bogen, S. A., I. Fogelman, and A. K. Abbas. 1993. Analysis of IL-2, IL-4, and IFN-γ-producing cells in situ during immune responses to protein antigens. J. Immunol. 150: 4197-4205.
45. Su, H. C., K. B. Nguyen, T. P. Salazar-Mather, M. C. Ruzek, M. Y. Dalod, and C. A. Biron. 2001. NK cell functions restrain T cell responses during viral infections. Eur. J. Immunol. 31: 3048-3055.
46. Rabinovich, B. A., J. Li, J. Shannon, R. Hurren, J. Chalupny, D. Cosman, and R. G. Miller. 2003. Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. J. Immunol. 170: 3572-3576.
47. bright natural killer cells mediate immunomodulatory effects of IL-2Rα- targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. USA 103: 5941-5946.
48. Wang, M., C. A. Ellison, J. G. Gartner, and K. T. HayGlass. 1998. Natural killer cell depletion fails to influence initial CD4 T cell commitment in vivo in exogenous antigen-stimulated cytokine and antibody responses. J. Immunol. 160: 1098-1105. (Pubitemid 28093403)
49. + T cells via OX40-OX40 ligand interactions. J. Immunol. 173: 3716-3724.
50. Cimolai, N., A. C. Cheong, B. J. Morrison, and G. P. Taylor. 1996. Mycoplasma pneumoniae reinfection and vaccination: protective oral vaccination and harmful immunoreactivity after re-infection and parenteral immunization. Vaccine 14: 1479-1483.
51. Simecka, J. W. 2003. Contrasting roles of immunity in mycoplasma respiratory disease. In Recent Research Developments in Infection and Immunity. S. G. Pandalai, ed. Transworld Research Network, pp. 203-219.